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OBJECTIVES: Approximately 20% of echocardiographic
imaging studies are suboptimal (inadequate visualization of
endocardial borders). Use of contrast agents reduces suboptimal
imaging and decreases frequency of follow-up testing. Given that
the ﬁnancial impact of increased use of contrast echocardiography
has not been fully explored, the objective of this study was to
evaluate the economics of introducing the contrast agent, per-
ﬂutren lipid microspheres (“PLM”), to an echocardiography
testing paradigm. METHODS: We developed an economic model
of echocardiographic imaging with PLM versus no contrast agent
in hospital outpatients. The model assumes a 100,000-member
health plan, with 4,000 members requiring initial non-contrast
echocardiography annually, of which 20% are suboptimal and
require follow-up testing. The ﬁrst round of follow-up testing is
assumed to be non-stress transthoracic echocardiography with or
without PLM. Up to one subsequent round of follow-up testing
was modeled, reﬂecting the range of current clinical practice
(i.e., repeat echocardiography, cardiac catheterization/coronary
angiography, nuclear imaging, cardiacMRI orCT).Default values
for procedure costs were estimated from 2008 CMS payment
rates; other clinical and cost data were derived from clinical trial
reports, published literature, and an expert panel survey. Sensitiv-
ity analysis was performed to assess the robustness of model
ﬁndings to variation in key model parameters. RESULTS: Use of
PLM versus no contrast agent was associated with approximately
81% (120 vs. 640) fewer follow-up tests. Associated annual cost
savings were approximately $114,000, or $143 on a per-patient
basis. Per-member-per-month (PMPM) costs of initial and subse-
quent follow-up testing in the 100,000-member plan were esti-
mated at $0.52 with PLM versus $0.61 when no contrast agent
was used. CONCLUSIONS: Because of its relatively low cost and
potential to obviate the need for more expensive and more inva-
sive examinations, perﬂutren lipidmicrospheresmay be an asset in
providing cost-effective cardiologic diagnoses in ﬁnancially-
conscious environments.
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Patients undergoing total hip replacement (THR) or total knee
replacement (TKR) surgery are considered to be at high risk of
venous thromboembolism (VTE). The current gold standard
of care in prevention of VTE (thromboprophylaxis) in these
patients is low-molecular-weight heparin (LMWH), which is
delivered by subcutaneous injection. Dabigatran etexilate (DBG)
is a novel, direct thrombin inhibitor which is administered
orally and does not require any monitoring. OBJECTIVES: To
evaluate the budgetary impact of DBG in local health econo-
mies. METHODS: Phase-III trials demonstrated that DBG is
as effective and safe as enoxaparin (LMWH). Therefore this
study concentrated on thromboprophylaxis costs most likely to
change dependant on the choice of thromboprophylactic,
namely, medication acquisition and administration. An interac-
tive model was developed, whereby the user can select a local
health economy (e.g. acute trust, NHS/independent centre,
primary care organisation etc.) anywhere in the UK and assess
the budgetary impact of the introduction of DBG based on local
THR/TKR procedure data. Several other inputs may also be
deﬁned, including current practice, take-up, ability to self-
administer, treatment duration and strategy. Unit costs were
derived from standard sources; other inputs were derived from
the published literature. RESULTS: Under default assumptions,
results for a large hypothetical centre performing 500 THR and
500 TKR procedures per year reveal that although the medica-
tion acquisition costs of DBG and LMWH are similar, the intro-
duction of DBG could potentially save up to 1500 community
nurse visits per annum. This translates into a budget savings
of approximately £44,000. CONCLUSIONS: Compared with
LMWH, centres that switch patients to DBG may decrease the
ﬁnancial burden placed on the local health economy by current
recommended practice in thromboprophylaxis following THR
and TKR. Through removal of costly administration, education
and home visits associated with LMWH, the resource savings
could be considerable.
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